Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Breast cancer
Closed
Phase 3
This trial is looking at adding a drug called pembrolizumab to chemotherapy and hormone therapy for newly diagnosed breast cancer.
It is for people whose cancer is HER2 negative and oestrogen (ER) positive. This means the breast cancer cells:
don’t have receptors for
do have receptors for
Recruitment start: 5 February 2019
Recruitment end: 15 August 2022
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Schmid
Merck Sharp & Dohme Ltd
Last reviewed: 30 June 2024
CRUK internal database number: 16042
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
